Web Analytics

Investor Profile

OrbiMed

OrbiMed United States - New York, NY
INVESTOR

1 Disclosed Funding Rounds $261,000,000
52 Participating Investments




OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds, and royalty/credit f

Invested In

Company Date Round Raised
  CHARM Therapeutics June, 09 ,2022 Series A $50,000,000
  Treeline Biosciences October, 18 ,2022 Series A $261,000,000
  Congruence Therapeutics March, 07 ,2023 Series A $65,000,000
  Delfi Diagnostics July, 18 ,2022 Series B $225,000,000
  Aer Therapeutics, Inc. April, 17 ,2023 Series A $36,000,000
  Pathalys Pharma February, 07 ,2023 Unknown $150,000,000
  Convergent Therapeutics, Inc. May, 04 ,2023 Series A $90,000,000
  CHARM Therapeutics June, 09 ,2022 Series A $50,000,000
  ADARx Pharmaceuticals Inc. August, 10 ,2023 Series C $200,000,000
  Congruence Therapeutics March, 07 ,2023 Series A $65,000,000
  Fore Biotherapeutics August, 25 ,2023 Series D $75,000,000
  Aer Therapeutics, Inc. April, 17 ,2023 Series A $36,000,000
  Epigenic Therapeutics August, 30 ,2023 Series A $32,000,000
  Convergent Therapeutics, Inc. May, 04 ,2023 Series A $90,000,000
  Star Therapeutics September, 05 ,2023 Series C $90,000,000
  ADARx Pharmaceuticals Inc. August, 10 ,2023 Series C $200,000,000
  Corteria Pharmaceuticals September, 07 ,2023 Series A $69,471,000
  Fore Biotherapeutics August, 25 ,2023 Series D $75,000,000
  ReCode Therapeutics September, 20 ,2023 Series B $50,000,000
  Epigenic Therapeutics August, 30 ,2023 Series A $32,000,000
  Adela, Inc. September, 26 ,2023 Unknown $48,000,000
  Star Therapeutics September, 05 ,2023 Series C $90,000,000
  Evozyne September, 28 ,2023 Series B $81,000,000
  Corteria Pharmaceuticals September, 07 ,2023 Series A $69,471,000
  Iambic Therapeutics October, 06 ,2023 Series B $100,000,000
  ReCode Therapeutics September, 20 ,2023 Series B $50,000,000
  Rampart Bioscience October, 25 ,2023 Series A $85,000,000
  Adela, Inc. September, 26 ,2023 Unknown $48,000,000
  Triveni Bio October, 27 ,2023 Series A $92,000,000
  Evozyne September, 28 ,2023 Series B $81,000,000
  Forward Therapeutics, Inc. November, 09 ,2023 Series A $50,000,000
  Iambic Therapeutics October, 06 ,2023 Series B $100,000,000
  Koya Medical, Inc. November, 16 ,2023 Unknown $30,000,000
  Rampart Bioscience October, 25 ,2023 Series A $85,000,000
  Odyssey Therapeutics December, 06 ,2023 Series C $101,000,000
  Triveni Bio October, 27 ,2023 Series A $92,000,000
  Noctrix Health, Inc. January, 17 ,2024 Series C $40,000,000
  Forward Therapeutics, Inc. November, 09 ,2023 Series A $50,000,000
  Sionna Therapeutics March, 07 ,2024 Series C $182,000,000
  Koya Medical, Inc. November, 16 ,2023 Unknown $30,000,000
  Capstan Therapeutics March, 21 ,2024 Series B $175,000,000
  Odyssey Therapeutics December, 06 ,2023 Series C $101,000,000
  Mirador Therapeutics March, 26 ,2024 Unknown $400,000,000
  Noctrix Health, Inc. January, 17 ,2024 Series C $40,000,000
  Alterome Therapeutics, Inc April, 09 ,2024 Series B $132,000,000
  Sionna Therapeutics March, 07 ,2024 Series C $182,000,000
  Scorpion Therapeutics July, 17 ,2024 Series C $150,000,000
  Capstan Therapeutics March, 21 ,2024 Series B $175,000,000
  Mirador Therapeutics March, 26 ,2024 Unknown $400,000,000
  Alterome Therapeutics, Inc April, 09 ,2024 Series B $132,000,000
  Scorpion Therapeutics July, 17 ,2024 Series C $150,000,000
  Candid Therapeutics September, 10 ,2024 Unknown $370,000,000